Natixis Advisors LLC Grows Stock Holdings in Charles River Laboratories International, Inc. $CRL

Natixis Advisors LLC increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,357 shares of the medical research company’s stock after buying an additional 9,397 shares during the period. Natixis Advisors LLC’s holdings in Charles River Laboratories International were worth $22,812,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its position in Charles River Laboratories International by 84.5% during the third quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after acquiring an additional 47,954 shares in the last quarter. Madison Asset Management LLC bought a new stake in Charles River Laboratories International during the third quarter worth $1,935,000. JPMorgan Chase & Co. raised its position in Charles River Laboratories International by 14.5% during the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after acquiring an additional 40,073 shares in the last quarter. Penserra Capital Management LLC bought a new stake in Charles River Laboratories International during the third quarter worth $533,000. Finally, Gotham Asset Management LLC raised its position in Charles River Laboratories International by 17.3% during the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock worth $49,403,000 after acquiring an additional 46,594 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the topic of several research analyst reports. Mizuho set a $192.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Barclays increased their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price objective on the stock. Finally, Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Price Performance

Shares of CRL opened at $181.46 on Friday. The firm has a market capitalization of $8.74 billion, a PE ratio of -48.26, a PEG ratio of 2.12 and a beta of 1.46. The company’s 50-day moving average is $171.37 and its 200-day moving average is $181.57. Charles River Laboratories International, Inc. has a fifty-two week low of $143.06 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.